Filtered By:
Management: Family Practices
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 250 results found since Jan 2013.
Reducing Ischemic Stroke in Diabetes: The Role of GLP-1 RAs
J Fam Pract. 2023 Jul;72(6 Suppl):S55-S60. doi: 10.12788/jfp.0624.ABSTRACTStroke is a significant cause of mortality worldwide, and diabetes is an independent risk factor for ischemic stroke occurrence and recurrence. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower the risk of ischemic stroke through beneficial effects on traditional stroke risk factors such as hyperglycemia, hypertension, and dyslipidemia. Primary care practitioners (PCPs) can play a substantial role in reducing ischemic stroke; studies have indicated that patients who have a PCP at the time of first stroke have a lower risk of stroke recurren...
Source: The Journal of Family Practice - August 7, 2023 Category: Practice Management Authors: John E Anderson Javed Butler Andrei V Alexandrov Source Type: research
Screening for undiagnosed atrial fibrillation using a single-lead electrocardiogram at primary care visits: patient uptake and practitioner perspectives from the VITAL-AF trial
This study assessed patient and primary care ...
Source: BMC Family Practice - June 30, 2023 Category: Primary Care Authors: Steven J. Atlas, Jeffrey M. Ashburner, Yuchiao Chang, Leila H. Borowsky, Patrick T. Ellinor, David D. McManus, Steven A. Lubitz and Daniel E. Singer Tags: Research article Source Type: research
Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
J Fam Pract. 2023 Jun;72(5):227-229. doi: 10.12788/jfp.0610.ABSTRACTYES. In patients with known cardiovascular disease (CVD), ezetimibe with a statin decreases major adverse cardiovascular events (MACE) but has no effect on all-cause and cardiovascular mortality, compared to a statin alone (strength of recommendation [SOR], A; meta-analysis of randomized controlled trials [RCTs] including 1 large RCT). In adults with atherosclerotic CVD (ASCVD), the combination of ezetimibe and a moderate-intensity statin (rosuvastatin 10 mg) was noninferior at decreasing cardiovascular death, major cardiovascular events, and nonfatal stro...
Source: The Journal of Family Practice - June 20, 2023 Category: Practice Management Authors: Vinay Reddy James Allison Anne Mounsey Source Type: research
